Combining Multiple Serum Biomarkers in Tumor Diagnosis: A Clinical Assessment

Simple item page
aut.relation.endpage160
aut.relation.issue1
aut.relation.startpage153
aut.relation.volume1
aut.researcherLu, Jun
dc.contributor.authorLi, X
dc.contributor.authorLu, J
dc.contributor.authorRen, H
dc.contributor.authorChen, T
dc.contributor.authorGao, L
dc.contributor.authorDi, L
dc.contributor.authorSong, Z
dc.contributor.authoret al
dc.date.accessioned2013-11-15T21:01:21Z
dc.date.available2013-11-15T21:01:21Z
dc.date.copyright2013
dc.date.issued2013
dc.description.abstractThe present study aimed to assess the diagnostic/ prognostic value of various clinical tumor markers, including carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cytokeratin 19 (CYFRA21-1), α-fetoprotein (AFP), carbohydrate antigen-125 (CA-125), carbohydrate antigen-19.9 (CA-19.9) and ferritin, individually or in combination. The electro-chemiluminescence immunization method was performed to detect the levels of seven tumor markers in 560 cancer patients and 103 healthy subjects for comparison. The serum levels of the seven markers measured in cancer patients were higher compared to healthy subjects (P<0.05 for AFP and P<0.001 for the remaining six markers). Different markers had different sensitivity towards different types of tumors. Combining more markers significantly increased the ratios of positive diagnosis in the tumors. The diagnostic sensitivities of combining seven markers were particularly high in digestive, urinary and skeletal tumors (82, 92 and 83%, respectively). Gynecological tumors have exhibited a constant yet relatively low positive diagnosis irrespective of the use of a single marker or combined markers. However, the increase in sensitivity when combining markers was accompanied by a decrease in specificity. Generally, combining more markers increased the tumor detection rates, while a combination of the seven markers provided the highest detection rate. Combined detection showed a particularly high sensitivity in detecting respiratory, digestive and urinary system tumors, with the lowest sensitivity observed in gynecological tumors. As a result, combining tumor markers may play an important role in early tumor detection/diagnosis while the loss of specificity can be tolerated.
dc.identifier.citationMolecular and Clinical Oncology, vol.1(1), pp.153 - 160
dc.identifier.doi10.3892/mco.2012.23
dc.identifier.urihttps://hdl.handle.net/10292/5890
dc.publisherSpandidos Publications
dc.relation.urihttps://www.spandidos-publications.com/10.3892/mco.2012.23
dc.rightsSpandidos Publications automatically provides open access to articles 12 months after their publication online.
dc.rights.accessrightsOpenAccess
dc.subjectTumor marker
dc.subjectDiagnosis
dc.subjectLung cancer
dc.subjectCarcinoembryonic antigen
dc.subjectNeuron-specific enolase
dc.subjectCytokeratin 19
dc.titleCombining Multiple Serum Biomarkers in Tumor Diagnosis: A Clinical Assessment
dc.typeJournal Article
pubs.elements-id130307
pubs.organisational-data/AUT
pubs.organisational-data/AUT/Health & Environmental Science
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Lu.pdf
Size:
364.67 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
licence.htm
Size:
30.34 KB
Format:
Unknown data format
Description:
Download
Collections
School of Interprofessional Health Studies